Clinical analysis of 138 multiple primary cancers diagnosed of digestive system malignant tumor initially
10.3760/cma.j.issn.0253-3766.2018.02.013
- VernacularTitle: 138例首发于消化系统的多原发癌临床分析
- Author:
Jiaming LYU
1
;
Huacai XIONG
1
;
Bo WU
2
;
Xiaoquan ZHOU
1
;
Jie HU
2
Author Information
1. First Clinical Medical College, Wenzhou Medical University, Wenzhou 325000, China
2. Department of Radiotherapy, Taizhou Central Hospital (Taizhou University Hospital), Taizhou 318000, China
- Publication Type:Clinical Trail
- Keywords:
Neoplasms, multiple primary;
Digestive system neoplasms;
Clinical characteristic;
Prognosis
- From:
Chinese Journal of Oncology
2018;40(2):147-150
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the clinical characteristics, strategy of treatment and prognosis of multiple primary cancers(MPC) diagnosed of digestive system malignant tumor firstly.
Methods:From January, 2000 to December, 2015, the clinical, follow-up and prognostic data of 138 MPC patients diagnosed of digestive system malignant tumor firstly were retrospectively analyzed.
Results:138 cases were found in 10 580 cases with malignant tumors, and the incidence was 1.30%. There were 129 cases of duplex primary cancers, 8 cases of triple primary cancers and 1 case of quintuple primary cancers. The repetitive primary cancer was occurred in digestive system (61cases, 44.2%) most frequently, with the next in respiratory system (46 cases, 33.3%). 52.2% (72 cases) suffered second primary cancer in 2 years after first primary cancer diagnosed, and 75.4% (104 cases) in 5 years. The median overall survival in patients with all cancer lesions radically treated was 168 months, better than any other treatment (68 months, P<0.05).
Conclusions:The second primary cancers of MPC cases initially diagnosed of digestive system malignant tumor most frequently occurred in the digestive system and respiratory system. More concern should be attracted in follow-up, especially in the first 5 years. The key to improve patient′ prognosis was radical treatment to every primary cancer.
